Epigen vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Epigen
Epigen is a member of the epidermal growth factor (EGF) family. It plays roles in skin regeneration and has been studied for wound healing and anti-aging applications.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | Epigen | PT-141 (Bremelanotide) |
|---|---|---|
| Mechanism | Binds to and activates the EGF receptor (EGFR), promoting cell proliferation, migration, and differentiation. Involved in skin homeostasis and repair processes. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Topical: Typically used at low concentrations (ppm to low %) in cosmetic formulations. Research applications vary. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Primarily topical application for skincare. Research may use other routes for systemic effects. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Topical use generally well-tolerated. Theoretical concerns about promoting cell proliferation. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
Both Epigen and PT-141 (Bremelanotide) are commonly used for: